Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 80,000 Shares

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel sold 80,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $8.14, for a total value of $651,200.00. Following the sale, the director now directly owns 1,888,886 shares of the company’s stock, valued at $15,375,532.04. This represents a 4.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Gautam Patel also recently made the following trade(s):

• On Wednesday, January 8th, Gautam Patel sold 62,590 shares of Amneal Pharmaceuticals stock. The shares were sold at an average price of $8.01, for a total value of $501,345.90.
• On Thursday, January 2nd, Gautam Patel sold 17,410 shares of Amneal Pharmaceuticals stock. The shares were sold at an average price of $8.01, for a total value of $139,454.10.

Amneal Pharmaceuticals Stock Down 0.1 %

Amneal Pharmaceuticals stock opened at $7.98 on Thursday. The firm has a 50 day moving average price of $8.15 and a 200-day moving average price of $8.24. Amneal Pharmaceuticals, Inc. has a twelve month low of $5.01 and a twelve month high of $9.48. The company has a market capitalization of $2.47 billion, a P/E ratio of -11.74 and a beta of 1.10.

Institutional Trading of Amneal Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Franklin Resources Inc. grew its stake in shares of Amneal Pharmaceuticals by 4.9% during the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock worth $778,000 after acquiring an additional 4,178 shares during the period. Gladius Capital Management LP bought a new position in Amneal Pharmaceuticals during the third quarter worth about $37,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in shares of Amneal Pharmaceuticals by 13.6% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company’s stock worth $366,000 after purchasing an additional 5,523 shares in the last quarter. Segall Bryant & Hamill LLC raised its position in shares of Amneal Pharmaceuticals by 1.6% in the third quarter. Segall Bryant & Hamill LLC now owns 489,162 shares of the company’s stock valued at $4,070,000 after purchasing an additional 7,661 shares during the period. Finally, Rhumbline Advisers boosted its holdings in Amneal Pharmaceuticals by 3.5% in the 4th quarter. Rhumbline Advisers now owns 232,264 shares of the company’s stock worth $1,840,000 after buying an additional 7,875 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on AMRX. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Piper Sandler increased their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.